Loading clinical trials...
Loading clinical trials...
A Multicenter Open-Label Interventional Biomarker Study of Lutikizumab in Adult Subjects With Moderate-to-Severe Hidradenitis Suppurativa or Adult Subjects With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Lutikizumab
Locations
2
United States
Physioseq, LLC /ID# 267266
Sacramento, California, United States
University of Michigan Health System - Ann Arbor /ID# 267275
Ann Arbor, Michigan, United States
Start Date
August 14, 2024
Primary Completion Date
February 1, 2027
Completion Date
February 1, 2027
Last Updated
January 24, 2025
NCT06116526
NCT06958211
NCT06461897
NCT06921850
NCT07262983
NCT06389136
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions